Therapeutic Potential of Natural Products in the Treatment of Schistosomiasis

Molecules. 2023 Sep 26;28(19):6807. doi: 10.3390/molecules28196807.

Abstract

It is estimated that 250 million people worldwide are affected by schistosomiasis. Disease transmission is related to the poor sanitation and hygiene habits that affect residents of impoverished regions in tropical and subtropical countries. The main species responsible for causing disease in humans are Schistosoma Mansoni, S. japonicum, and S. haematobium, each with different geographic distributions. Praziquantel is the drug predominantly used to treat this disease, which offers low effectiveness against immature and juvenile parasite forms. In addition, reports of drug resistance prompt the development of novel therapeutic approaches. Natural products represent an important source of new compounds, especially those obtained from plant sources. This review compiles data from several in vitro and in vivo studies evaluating various compounds and essential oils derived from plants with cercaricidal and molluscicidal activities against both juvenile and adult forms of the parasite. Finally, this review provides an important discussion on recent advances in molecular and computational tools deemed fundamental for more rapid and effective screening of new compounds, allowing for the optimization of time and resources.

Keywords: essential oil; molecular tools; natural compounds; schistosomiasis.

Publication types

  • Review

MeSH terms

  • Animals
  • Anthelmintics* / pharmacology
  • Anthelmintics* / therapeutic use
  • Biological Products* / pharmacology
  • Biological Products* / therapeutic use
  • Humans
  • Praziquantel / pharmacology
  • Schistosoma haematobium
  • Schistosoma mansoni
  • Schistosomiasis* / drug therapy
  • Schistosomiasis* / parasitology

Substances

  • Anthelmintics
  • Biological Products
  • Praziquantel

Grants and funding

This research received no external funding.